Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 399

Results For "CE"

9028 News Found

Lupin to foray into the digital healthcare space
Digitisation | June 03, 2021

Lupin to foray into the digital healthcare space

The company recently incorporated a new entity in the name of Lupin Digital Health Limited


Zydus Cadila receives tentative approval from USFDA for lung cancer drugs
Policy | June 03, 2021

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs

Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors


Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore
News | June 03, 2021

Panacea Biotec posts consolidated Q4FY21 loss of Rs. 54.14 crore

The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021


Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India
News | June 03, 2021

Sun Pharma and Ferring Pharmaceuticals to introducing CARITEC in India

Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC


Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna
News | June 03, 2021

Lonza to expand manufacturing drug substance for COVID-19 Vaccine Moderna

Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Sun Pharmaceutical’s internals remain strong: ICICI Securities
News | May 31, 2021

Sun Pharmaceutical’s internals remain strong: ICICI Securities

US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio


Shilpa Medicare Jadcherla facility gets GMP certification from Russia
Policy | May 29, 2021

Shilpa Medicare Jadcherla facility gets GMP certification from Russia

The GMP certificate is valid for three years until April 2024.


SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr
News | May 29, 2021

SMS Pharmaceuticals posts Q4FY21 consolidated PAT of Rs. 22.21 Cr

It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021


Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%
News | May 28, 2021

Zydus Cadila's COVID Vaccine in advance stage of trial; Q4 FY21 income up 3%

The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year